MedTrace Logo

Study to Examine the Effects of MultiStem in Ischemic Stroke

NCT01436487 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 134

Last updated 2016-08-02

No results posted yet for this study

Summary

A study to examine the safety and potential effectiveness of the adult stem cell investigational product, MultiStem, in adults who have suffered an ischemic stroke. The hypothesis is that MultiStem will be safe and provide benefit following an ischemic stroke.

Conditions

Interventions

BIOLOGICAL

MultiStem

single infusion 1-2 days following ischemic stroke

BIOLOGICAL

Placebo

single infusion 1-2 days following ischemic stroke

Sponsors & Collaborators

  • Medpace, Inc.

    collaborator INDUSTRY

  • Healios K.K.

    lead INDUSTRY

Principal Investigators

  • Robert W Mays, PhD · Healios K.K.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
83 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-10-31
Primary Completion
2015-03-31
Completion
2015-12-31

Countries

  • United States
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01436487 on ClinicalTrials.gov